Home
Companies
Catalysts
Deep Dives
MARITIME-ASCVD
PHASE3
ACTIVE
Drug:
MariTide
·
AMGN
Study Design
Design
Randomized, double-blind, placebo-controlled, event-driven outcomes trial
NCT
NCT07160257
Treatment Arms
MariTide
SC (dose TBD)
Placebo
Placebo SC
Primary Endpoints
[{"id":"mace","name":"Major adverse cardiovascular events (MACE)","type":"PRIMARY","results":[],"description":"CV outcomes in patients with established ASCVD. SELECT (semaglutide): 20% MACE reduction set the precedent."}]
Assessment
Enrolling. Long-duration outcomes trial. Readout likely 2029+. Source: ClinicalTrials.gov NCT07160257
Background & Context
CV outcomes trial for label claim. SELECT trial established GLP-1 MACE benefit.
Data from Supabase · Updated 2026-03-24